<<Disclaimer: Verify this information before applying it to your situation.>>

This is an interesting article that unfortunately seems to have some
misinformation about CD.
The full text is at http://www.truthabouttrade.org/article.asp?id=2460

These excerpts show their errors. On the web site you can send comments.
Some kindly worded corrections would be great.

>>That would change if the industry simply changed focus to orphan crops.
Such products would be, conceptually, diametrically opposite to anything
agbiotech has produced up to now. By direct analogy with orphan drugs,
orphan crops would address unmet needs in narrow markets, such as the
specialist nutrition market. Cow's milk for the lactose-intolerant, for
example, or peanuts purged of life-threatening allergens. Exotic GM wheats
for those with celiac disease (a particularly European problem).
Low-phenylalanine foodstuffs for people with phenylketonuria. With more than
20 years of recombinant plant development now behind us, these types of
products ought to be possible.

>>The markets would be relatively small: celiac disease affects around 1 in
250 Europeans, and is 20 times rarer in the United States; phenylketonuria
occurs in 1 in 10,000 or 1 in 25,000 people, depending on geography. But
rarity is a good thing in the context of GM food. It would be good PR if GM
crops were aimed only at a fraction of needful consumers rather than the
entire population; Europeans would be less likely to feel that GM staples
were being surreptitiously foisted on them. And it would be difficult for
activists to turn public opinion against such products because they would be
fighting against the interests of disadvantaged individuals with dietary
problems.

-Michael Thorn

* All posts for product information must include the applicable country *